Sat, Apr 19, 2014, 10:52 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

littlefeet155 73 posts  |  Last Activity: Apr 9, 2014 10:55 AM Member since: May 23, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Last fall Piper Jaffery said : " Erosive Osteoarthritis. Piper said it had no value for Erosive Osteoarthritis in its model " The Overweight is for the OTHER 6 Indications", Bet the Bakers are buying - they always do when there is a correction.. In 3-4 days a "surprise! SEC document will verify buying by the smart money. Fear is a tool large Institutions use all the time..Please sell me your shares!

  • littlefeet155 by littlefeet155 Mar 5, 2014 7:03 PM Flag

    Todays news was widely expected.The osteo indication wasn't even valued in many analysts reviews.So why the big hit? How much has XOMA gone up in the last 3 months? 120%...@ 6.90 XOMA is a double from last falls placement..I realize for longtime reversed split shareholders this is painful ,but the big money took profits AND secured a larger position imho.The volume was 4X normal giving plenty of trading power in the future. Todays news was for positioning when the real news which is coming up will do a similar move up.

  • Reply to

    Whogo and I nailed it on the Bakers 7 months ago

    by fezziwig2008 Dec 19, 2013 11:21 PM
    littlefeet155 littlefeet155 Mar 7, 2014 8:04 AM Flag

    Baker Bros trivia They own 25% of XOMA. Want to see a really undervalued BBplay? Check out Genomic Health which the Bakers have purposely suppressed the share price for guess what happens next . The Bakers own 48% of Genomic Health. Contrary to popular myth ,although the Bakers own a wide portfolio, most of their billions are tied up in 7 or 8 companies. XOMA and GHDX are 2 of their biggest investments...unless you look at the last 3 days vs the last 3 years.

  • Reply to

    Varian sells another 20,000

    by frankyassissi Mar 20, 2014 3:42 PM
    littlefeet155 littlefeet155 Mar 20, 2014 4:07 PM Flag

    Hey aswipe.He cashed in options and has 300k left.What are you stupid or sumthing?

  • No,the Bakers who have added to XOMA are up 300% in the last 2 years.Instant gratifgarbage. They own 25% of XOMA. Want to see a really undervalued BB play? Check out Genomic Health which the Bakers have purposely suppressed the share price for guess what happens next . The Bakers own 48% of Genomic Health. Contrary to popular myth ,although the Bakers own a wide portfolio, most of their billions are tied up in 7 or 8 companies. XOMA and GHDX are 2 of their biggest investments...unless you look at the last 3 days vs the last 3 years.

  • Reply to

    Everything is Gone!

    by daviscupper Mar 4, 2014 6:05 PM
    littlefeet155 littlefeet155 Mar 4, 2014 9:28 PM Flag

    dude! I need to know what you doin? coke?

  • Piper Jaffray recommends buying shares of XOMA on any weakness following the company's Phase II data on gevokizumab in Erosive Osteoarthritis. Piper said it had no value for Erosive Osteoarthritis in its model and reiterates an Overweight rating on the stock.

  • littlefeet155 by littlefeet155 Mar 11, 2014 10:29 AM Flag

    I have owned 5 BB stocks and they play both sides of the trade to manipulate profits and acquire stock.They push it up go short put out bad press ( look at how much they bought of XOMA on the phase2 - WE DONT GIVE ACHT ABOUT THAT INDICATION) "poor results.They are doing it right here and will take it back to 9 with good news all the while making money both ways and acquiring the company. ..They own about a third of XOMA and they act just like every other sleezebag (Cramer a good example) that plays Wall Street

  • A 38 % retrace is $6.85... and they will get close. For those who laugh at these clowns who do not understand tis is a red herring- its a buying opportunity. Cash in hand early tomorrow morning .

  • littlefeet155 littlefeet155 Mar 4, 2014 7:34 PM Flag

    A 38 % retrace is $6.85... and they will get close. For those who laugh at these clowns who do not understand tis is a red herring- its a buying opportunity. Cash in hand early tomorrow morning .

  • littlefeet155 by littlefeet155 Mar 14, 2014 10:34 AM Flag

    Retail really hasn't participated as in the past. Retail that are in are subject to the manipulation of the market.HALO is one of the best bios in development and that fact may help position you wisely. I guess I could put up tons of charts showing how a bio, about to be bought out is first killed so the now savvy Institutions now make money going 3 ways ......

  • Announced the selection of pyoderma gangrenosum (PG) as its next Phase 3 indication for gevokizumab based upon the compelling results generated from 6 patients enrolled in the Company's PG clinical pilot program. In March 2014, the results will be shared with the FDA to determine the Phase 3 clinical protocol at an End of Phase 2 meeting. PG is one of a cluster of diseases under the umbrella of neutrophilic dermatosis.
    Reported Phase 2 data from the Company's gevokizumab study in patients with moderate to severe inflammatory acne and completed a thorough analysis of the acne market. Rather than pursuing the broader acne indication, the Company will consider focusing on less prevalent but more severe acne indications that also are considered indications under the neutrophilic dermatosis umbrella.
    Reported promising results in October 2013, from the Day 84 pain and function endpoint in the Company's gevokizumab Phase 2 study in patients with erosive osteoarthritis of the hand (EOA) and elevated C-reactive protein (CRP). Completed enrollment in a supplemental study in patients with EOA and non-elevated CRP. On March 4, 2014, XOMA reported that despite early positive results, the top-line data at Day 168 in the initial study, as well as at Day 84 in the supplemental study, were not positive and led to the Company's decision not to pursue the broad EOA indication for Phase 3 testing. The Company will continue to review the data to determine if there is a specific segment of the EOA population that could benefit from gevokizumab therapy.
    Increased the pace of enrollment at 70 U.S. study sites participating in the gevokizumab EYEGUARD™-A and EYEGUARD-C studies.
    XOMA's partner, SERVIER, continued to enroll patients in EYEGUARD-B, which is studying gevokizumab in patients who have non-infectious uveitis with underlying Behçet's disease, a rare indication.
    As of yearend, SERVIER had obtained approvals in 15 countries to conduct the EYEGUARD-A and

  • littlefeet155 by littlefeet155 Mar 10, 2014 10:48 AM Flag

    A double + in the past few months a 50% correction and fear.So typical and the perfect setup for the news about to come. I bought the last 2 offerings along with the Bakers. We dont care what the price is today we care what it is when we sell, and we havnt sold a share, but if you would like to sell me your shares I will gladly buy them from you because if there is one thing I cant stand is a scared shareholder

  • littlefeet155 littlefeet155 Mar 5, 2014 2:59 AM Flag

    yes the quote is from last Aug because thats how long ago Piper Jaffery said : " Erosive Osteoarthritis. Piper said it had no value for Erosive Osteoarthritis in its model " The Overweight is for the OTHER ^ Indications, bet the Bakers are buying - the always do when there is a correction.

  • littlefeet155 littlefeet155 Mar 4, 2014 8:07 PM Flag

    it would be worth noting that Piper raised their price target since then, so get a clue

  • Reply to

    those are strong data

    by garygirdhari Mar 6, 2014 9:21 AM
    littlefeet155 littlefeet155 Mar 6, 2014 10:00 AM Flag

    XOMA only needs 2 of the 6 possibilities .Yesterdays osteo was never given much of a shot and was used for the SECOND time on unsuspecting shareholders to believe XOMA drug is not a winner.

  • Reply to

    Big after hours

    by james08099 Mar 21, 2014 4:29 PM
    littlefeet155 littlefeet155 Mar 21, 2014 10:00 PM Flag

    its the triple witching orders forgetabout it.Trading was controlled by them. News will set you free

  • littlefeet155 littlefeet155 Mar 4, 2014 8:06 PM Flag

    PART 2
    to conduct the EYEGUARD-A and -C clinical trials. These countries represent 53 clinical study centers.
    SERVIER initiated enrollment in three of its independent gevokizumab POC studies: polymyositis/dermatomyositis, Schnitzler's syndrome, and giant cell arteritis.
    Strengthened the Company's financial position by raising $83.0 million in two public equity offerings, after deducting offering fees and out of pocket expenses.
    Received $8.6 million in milestone payments from 2 collaborators and licensees.
    Was awarded a patent for XOMA's flexible manufacturing system.
    "In 2013, our Proof-of-Concept program has provided us the evidence to support what we have known for some time, that gevokizumab has strong biological activity. In every patient population we have studied, we see a biological response to our compound, even if the results are not strong enough to pursue Phase 3 development in large patient populations. We were extremely excited by the dramatic results we achieved in the first six patients with pyoderma gangrenosum and have chosen this indication for pivotal development. We are looking forward to receiving the FDA's feedback on the data and its requirements for a Phase 3 clinical program in this underserved patient population," stated John Varian, Chief Executive Officer of XOMA. "We have identified other indications under the neutrophilic dermatoses classification that we hope to study in similar pilot studies with the goal of identifying others that are of value to pursue in Phase 3 development.

  • This indication was never valued there are 6 coming that are real drivers for XOMA. Fear from being stupid is just what the Bakers want.Betcha they increase their holdings in the 48 hours.

  • littlefeet155 littlefeet155 Mar 4, 2014 5:52 PM Flag

    Erosive Osteoarthritis IS NOT OR HAS BEEN THE MODEL DRIVER

INSM
13.41+0.88(+7.02%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.